close

Encorium Group, Inc. designs and manages clinical trials for pharmaceutical, biotechnology, and medical device industries primarily in Europe. The company's clinical research and development services supporting Phase I through Phase IV clinical trials include data management, such as CRF review and tracking, data entry, clinical/statistical reports, and writing manuscripts for publication; and biostatistics for the use of professionals to develop and review protocols, design analysis plans, and report formats in various phases of drug development. Its services also include strategic trial planning; project management; medical writing; quality assurance and compliance, such as investigator audits, pre-submission protocol compliance audits, and GCP audits; outsourcing clinical staff; and clinical trials management comprising case report form design, investigator recruitment, patient enrollment, and study monitoring and data collection. In addition, Encorium's services include study protocol design; medical and regulatory affairs, such as regulatory strategy formulation, new drug and biologic license application document preparation and review, and quality assurance and liaison; pharmacovigilance; compliance and medical report writing; patient registries; and medical device certification. It also licenses Oracle Clinical and Datafax as its clinical trials management systems. Encorium offers clinical trial services in various therapeutic areas, such as cardiovascular, nephrology, endocrinology/metabolism, hematology, diabetes, neurology, oncology, immunology, vaccines, infectious diseases, gastroenterology, dermatology, hepatology, rheumatology, urology, ophthalmology, women's health, and respiratory medicine. It was formerly known as Covalent Group, Inc. and changed its name to Encorium Group, Inc. in October 2006 in connection with the acquisition of Remedium Oy. The company was founded in 1989 and is headquartered in Wayne, Pennsylvania.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.65
Volume	6265
Volume Avg	22439
52 Week High	6.38
52 Week Low	0.23
PE	N/A
PE (group average)	N/A
EPS Year	-1.43
EPS change Q/Q	-137.5%
EPS change Q/Q Yr ago	-612.5%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-282.65%
REV change Q/Q	-29.41%
REV change Q/Q Yr ago	-36.84%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%